Valeant Pharmaceuticals Provides Efinconazole Update

LAVAL, Quebec, May 2, 2013 /CNW/ - Valeant Pharmaceuticals International, Inc. 
(NYSE: VRX) (TSX: VRX) announced that we agreed this afternoon that the launch 
of efinaconazole, our topical product candidate for the treatment of 
onychomycosis, will not occur until after the September 2013 arbitration 
hearing to resolve the breach of contract dispute with Anacor Pharmaceuticals 
(NASDAQ: ANAC). As a result, the preliminary injunction hearing which was 
scheduled for May 6-8, 2013 has been canceled. Valeant intends to vigorously 
contest Anacor's claims and continues to expect to launch the product in 2013. 
About Valeant 
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational 
specialty pharmaceutical company that develops, manufactures and markets a 
broad range of pharmaceutical products primarily in the areas of dermatology, 
neurology and branded generics. More information about Valeant can be found at 
Forward-looking Statements 
This press release may contain forward-looking statements, including, but not 
limited to, statements regarding our expectation with respect to the FDA 
response and our launch plans with respect to efinaconazole.  Forward-looking 
statements may generally be identified by the use of the words "anticipates," 
"expects," "intends," "plans," "should," "could," "would," "may," "will," 
"believes," "estimates," "potential," "target", or "continue" and variations 
or similar expressions. These statements are based upon the current 
expectations and beliefs of management and are subject to certain risks and 
uncertainties that could cause actual results to differ materially from those 
described in the forward-looking statements. These risks and uncertainties 
include, but are not limited to, risks and uncertainties discussed in the 
Company's most recent annual or quarterly report and detailed from time to 
time in Valeant's other filings with the Securities and Exchange Commission 
and the Canadian Securities Administrators, which factors are incorporated 
herein by reference. Rears are cautioned not to place undue reliance on any of 
these forward-looking statements. These forward-looking statements speak only 
as of the date hereof.  Valeant undertakes no obligation to update any of 
these forward-looking statements to reflect events or circumstances after the 
date of this press release or to reflect actual outcomes. 
Contact Information: Laurie W. Little  949-461-6002 
SOURCE: Valeant Pharmaceuticals International, Inc. 
To view this news release in HTML formatting, please use the following URL: 
CO: Valeant Pharmaceuticals International, Inc.
ST: Quebec
-0- May/03/2013 00:15 GMT
Press spacebar to pause and continue. Press esc to stop.